Back HIV/AIDS

HIV / AIDS

AIDS 2016: Long-Acting Injectable Drugs Work Well for HIV Maintenance Therapy

A pair of long-acting injectable antiretrovirals -- cabotegravir and rilpivirine -- administered once every 4 or 8 weeks maintained viral suppression in people who switched regimens with undetectable viral load, according to 48-week results from the LATTE-2 trial presented at the 21st International AIDS Conference (AIDS 2016) this week in Durban. A related qualitative analysis showed that study participants preferred long-acting injectables over pills for several reasons.

alt

AIDS 2016: Young Gay Men Can Do Well on PrEP, But May Need More Support

Young gay and bisexual men had good adherence to Truvada for pre-exposure prophylaxis (PrEP) during the first few months of a demonstration project with close monitoring, but adherence slipped once follow-up switched from monthly to quarterly, suggesting that young people using PrEP may require more on-going support, according to a presentation at the 21st International AIDS Conference (AIDS 2016) this week in Durban.

alt

AIDS 2016: PrEP Use Exceeds 79,000 in U.S., But Some Groups Lagging Behind

More than 79,000 people in the U.S. have started Truvada for pre-exposure prophylaxis (PrEP) over the past 4 years, according to the latest results from a survey of retail pharmacies by Gilead Sciences, presented today at the 21st International AIDS Conference (AIDS 2016) in Durban. Yet while large gains in PrEP use have been seen among men in cities with large gay communities, some groups are not benefitting as much as they could.

alt

AIDS 2016: PrEP Can Further Reduce HIV Risk After Partner Starts Antiretroviral Treatment

Offering Truvada pre-exposure prophylaxis (PrEP) to the HIV-negative partner in a serodiscordant couple during the first 6 months after the HIV-positive partner starts antiretroviral therapy (ART) can serve as a "bridge" to further reduce the likelihood of HIV infection, researchers reported at the 21st International AIDS Conference (AIDS 2016) taking place this week in Durban, South Africa.

alt

AIDS 2016: Researchers Now Focusing on Best Ways to Get PrEP to People Who Need It

Speaking to a pre-conference meeting on HIV pre-exposure prophylaxis (PrEP) ahead of the 21st International AIDS Conference (AIDS 2016), International AIDS Society president Chris Beyrer reminded delegates that when the International AIDS Conference was last held in Durban in the year 2000, the event was notable for drawing attention to the enormous gap in access to HIV treatment between rich and poorer countries. That conference began the treatment access era. "Now is really the time to start the PrEP access era," Beyrer said.

alt

AIDS 2016: Young Women Treated Very Early Stay HIV Negative and Preserve Immune Function

A group of youngSouth African women who were diagnosed during very HIV early infection and immediately given antiretroviral therapy (ART) preserved their CD4 cell counts and the function of cells that HIV normally disrupts, according to a study presented at the 2016 Towards an HIV Cure Symposium, which preceded the 21st International AIDS Conference this week in Durban, South Africa. The majority of them never seroconverted, staying HIV-negative despite having evidence of low levels of HIV infection in their cells.

alt

AIDS 2016: Progress Towards 90-90-90 Targets is Promising, But Funding Is the Critical Step

The United Nations 90-90-90 targets for HIV testing, treatment, and viral suppression are achievable by 2020 in many high-burden countries, but donor retreat is now the biggest threat to widespread success, delegates agreed at the UN 90-90-90 Target Workshop ahead of the 21st International AIDS Conference (AIDS 2016) in Durban.

alt